Journal of Orthopaedic Trauma

Home Current Issue Previous Issues For Authors Journal Info
Skip Navigation LinksHome > October 2008 - Volume 22 - Issue 9 > Platelet-Rich Concentrate Supports Human Mesenchymal Stem Ce...
Journal of Orthopaedic Trauma:
October 2008 - Volume 22 - Issue 9 - pp 595-604
doi: 10.1097/BOT.0b013e318188dbb7
Original Article

Platelet-Rich Concentrate Supports Human Mesenchymal Stem Cell Proliferation, Bone Morphogenetic Protein-2 Messenger RNA Expression, Alkaline Phosphatase Activity, and Bone Formation In Vitro: A Mode of Action to Enhance Bone Repair

Parsons, Philippa PhD; Butcher, Andrew BSc; Hesselden, Katy BSc; Ellis, Keith MSc; Maughan, Jonathan BSc; Milner, Richard PhD; Scott, Marcus PhD; Alley, Carie MSc; Watson, J Tracy MD; Horner, Alan PhD

Collapse Box

Abstract

Objective: Platelet-rich concentrate (PRC) is an autologous growth factor preparation that is in routine use for orthopaedic and maxillofacial surgery. However, there are little data available describing the cellular and molecular mechanisms by which PRC enhances the healing response in an osseous environment. The aim of this study was to identify cellular and molecular events that are modulated in human mesenchymal stem cells (hMSCs) in response to exposure to human PRC generated by a novel filtration-based device (CAPTION, Smith & Nephew Inc).

Methods: PRC and serum were prepared from blood donated by 11 volunteers. Growth factor content and release from PRC were determined by enzyme-linked immunosorbent assay. Cell proliferation was quantified by DNA content and osteoblastic differentiation by alkaline phosphatase expression and mineralized nodule formation. Real-time reverse transcription-polymerase chain reaction analysis was used to determine the early molecular pathways regulated in hMSCs by PRC.

Results: The results obtained confirm previous in vitro and in vivo observations demonstrating that PRC enhances hMSC proliferation. Furthermore, our data suggest that when added as a clot, PRC induces an earlier onset of proliferation compared with serum without leading to cell overgrowth and the inhibition of cell differentiation. At the molecular level, PRC treatment stimulated a transient enhancement of bone morphogenetic protein-2 messenger RNA that peaked after 12 hours and induced an earlier and a sustained increase in the key osteogenic transcription factor RUNX2. By 3 days of treatment, PRC enhanced alkaline phosphatase activity more than 2-fold compared with donor-matched serum, and at 23 days, the increase in osteoblastic commitment translated to enhanced calcified matrix deposition.

Conclusions: Taken together, the data presented here suggest that treatment of hMSC with clotted PRC, in an osteoinductive environment, enhances osteoblastic commitment and bone formation. Furthermore, these data indicate that the enhanced osteogenesis seen in the presence of PRC cannot be explained solely by enhanced cell proliferation, suggesting that PRC modulates a number of cell and molecular pathways to promote bone formation.

© 2008 Lippincott Williams & Wilkins, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Article Tools

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.